IML  is a new anti-inflammatory drug based on a low-toxic derivative (ester) of indomethacin. IML ensures prolonged release, high bioavailability and targeted delivery, while also minimizing systemic toxicity by reducing indomethacin concentration in the blood.

Main advantages (confirmed in preclinical studies):

−Prolonged and potent anti-inflammatory action after single use.

−Low toxicity towards the gastrointestinal tract (doesn’t cause ulcers and bleeding) compared to non-selective NSAIDs.


Thanks to its high efficacy and safety, IML may be used to treat chronic inflammatory diseases (such as rheumatoid arthritis, gout and others), unlike the known NSAIDs, which are suitable only for short-term use due to their toxicity.

Current status: API and oral dosage form are developed. Preclinical studies are completed. Documents are prepared for obtaining Phase I clinical trial permission in Russia.

Intellectual property:

  • Russian patent RU 2685257, РСТ/RU2018/000884,
  • patenting ongoing in the USA, EU, China and other countries.

Investments and commercialization prospects:

– Russia – the project is open for Russian investors/pharmaceutical companies, interested in purchasing the rights to Russian and EAEU markets. Investment requirements are 130M RUB (up to drug registration). Drug sales starting in 2024. Potential sales at Russian and EAEU markets may exceed 0.5 billion RUB/year.

– Global market – the project is open for venture investors, interested in developing the project at key foreign markets (USA, EU, China, India, etc). Investment requirements are $10-15M during 2021-2023 (up to the completion of Phase II clinical trials). Potential growth in project value is over $0.5 billion.